Skip to main content

Share story

Products Policy

Paramount settles state challenge to $110 billion Warner Bros. Discovery deal

Paramount logo on a blue background. Image: Primary
Paramount reached a proposed settlement with California and 11 other states that removes their antitrust lawsuit as an obstacle to its planned $110 billion acquisition of Warner Bros. Discovery. The consent decree requires minimum theatrical output for five years, including 30 films in each of the first two years and 32 annually afterward, plus at least $300 million in additional U.S. production spending compared with 2025. Missing a required film would trigger a $30 million payment per film and require Paramount to divest Miramax. The agreement also preserves a free streaming service and establishes an editorial-independence board for CBS and CNN, but it still requires court approval.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from The Verge and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Security Infrastructure
Security Infrastructure

Ransomware attack halts trading on Nepal Stock Exchange

The Nepal Stock Exchange suspended all Monday trading after ransomware hit infrastructure hosting the trading systems of 72 brokerages. Data Hub detected the attack early that morning and kept affected systems offline while invest...

Security
Security

Gyazo breach exposed metadata for 490 million images

A breach at screenshot-sharing service Gyazo exposed nearly 24 million customer records and an additional 490 million image-metadata records, Infosecurity Magazine reported. Attackers exploited an upload-server vulnerability, gain...

AI Products
AI Products

Tech groups use residual-value guarantees to lower AI financing costs

Large technology companies are increasingly using residual-value guarantees to finance AI equipment off their balance sheets, the Financial Times reports. The guarantees apply the companies' credit strength to the hardware's futur...

Capital Products
Capital Products

Novadip raises €10.4 million to complete pivotal bone-graft trial

Belgian regenerative-medicine company Novadip Biosciences has closed a €10.4 million convertible financing led by New Science Ventures. The funding will support completion of an ongoing Phase 3 trial in the United States and Europ...